Lung cancer trial: does adding a second drug boost survival?
NCT ID NCT03896074
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial compares the drug atezolizumab alone versus atezolizumab plus bevacizumab as a first treatment for people with advanced non-small-cell lung cancer that has a specific marker (PD-L1). About 206 patients are taking part. The main goal is to see if the combination helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab and bevacizumab
- What this could lead to
- If it works, this could point toward a more effective first-line treatment for advanced non-small-cell lung cancer.
- What could go wrong
- This is a Phase 2 trial with 206 participants, so results are still early. The combination may not improve survival and could add side effects like bleeding or high blood pressure from bevacizumab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O. Per l' emergenza Cannizzaro
Catania, 95126, Italy
-
A.O.U. Policlinico - Vittorio Emanuele- Presidio Ospedaliero Gaspare Rodolico
Catania, CT, 95125, Italy
-
AO Papardo
Messina, 98158, Italy
-
AOU Ospedali Riuniti "Umberto I- G.M.Lancisi-G.Salesi"
Ancona, 60020, Italy
-
AOU S. Luigi Orbassano
Orbassano, 10043, Italy
-
ASST Sette Laghi
Varese, 21100, Italy
-
AUOI di Verona- Borgo Trento
Verona, 37126, Italy
-
AUSL della Romagna
Ravenna, RA, 48121, Italy
-
AUSL di Teramo - Ospedale "Giuseppe Mazzini"
Teramo, TE, 64100, Italy
-
AZIENDA USL DI PIACENZA-Ospedale Guglielmo da Saliceto
Piacenza, PC, 29121, Italy
-
Arcispedale Santa Maria Nuova
Reggio Emilia, 42100, Italy
-
Asst Di Lecco
Lecco, CM, 23900, Italy
-
Azienda Ospedaliera Dei Colli V.Monaldi
Naples, 80131, Italy
-
Azienda Ospedaliera S.Giovanni Addolorata
Roma, RM, 00184, Italy
-
Azienda Ospedaliera San Camillo-Forlanini
Roma, Roma, 00152, Italy
-
Azienda Ospedaliero-Universitaria Di Modena
Modena, MO, 41124, Italy
-
C.R.O.B. - I.R.C.C.S.
Rionero in Vulture, PZ, 85028, Italy
-
Fondazione IRCCS - San Gerardo del Tintori
Monza, MILANO, 20900, Italy
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Fondazione PTV - POLICLINICO TOR VERGATA
Roma, RM, 00133, Italy
-
IRCCS ISTITUTO Oncologico Veneto
Padova, 35128, Italy
-
IRCCS Oncologico Istituto Tumori "Giovanni Paolo II"
Bari, 70124, Italy
-
IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, 71013, Italy
-
Irccs S.R.L. Irst
Meldola, 47014, Italy
-
Istituto Nazionale Tumori di Napoli IRCCS Pascale
Naples, 80131, Italy
-
OSPEDALE SAN PAOLO - ASL Roma 4
Civitavecchia, RM, 00053, Italy
-
Ospedale Degli Infermi Di Biella
Ponderano, BI, 13875, Italy
-
Ospedale Della Misericordia
Grosseto, GR, 58100, Italy
-
Ospedale S.G. Moscati
Statte, TA, 74010, Italy
-
Ospedale Sacro Cuore- Don Calabria
Negrar, 37024, Italy
-
P.O. Antonio Perrino
Brindisi, 72100, Italy
-
P.O. Umberto I
Syracuse, SR, 96100, Italy
-
Presidio Ospedaliero Unico Av3 - Ospedale Generale Provinciale - Macerata
Province of Macerata, MC, 62100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.